<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428935</url>
  </required_header>
  <id_info>
    <org_study_id>CCRI IRB05-00118</org_study_id>
    <nct_id>NCT00428935</nct_id>
  </id_info>
  <brief_title>Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy</brief_title>
  <official_title>Phase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asklepios Biopharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of a miniature dystrophin gene in the
      treatment of progressive muscle weakness due to Duchenne Muscular Dystrophy (DMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I randomized double blind dose escalation study investigates the safety and
      efficacy of the mini-dystrophin gene transferred to the biceps muscle for Duchenne muscular
      dystrophy patients, ages 5 to 12 years of age, using a recombinant adeno-associated virus.
      Eligible participants must have a known dystrophin gene mutation and may be concurrently
      treated with corticoid steroids. The mini-dystrophin gene or a placebo agent (normal saline
      or empty viral capsids) are injected directly into both biceps muscles while under conscious
      sedation. Following the gene transfer, patients are admitted to the hospital for 48 hours of
      observation followed by weekly outpatient visits at the Columbus Children's Hospital
      Neuromuscular Clinic. A bilateral muscle biopsy is preformed following 6 weeks with long term
      follow up will consisting of bi-annual visits for the next 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>followed for 2 years post injection</time_frame>
    <description>Physical Exams assessing major organ systems and safety labs (GGT, Bilirubin, Glucose, Amylase, CBC/Diff, AFP, Platelets, PT/PTT, Creatinine, Electrolytes, Total protein, Alkaline phosphatase, and Urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mini-dystrophin gene expression at the site of gene transfer</measure>
    <time_frame>90 days post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Volume Isometric Contraction Testing as a measure of muscle strength</measure>
    <time_frame>out to 2 years post injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose cohort - 2.0E10 vg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose - 1.0E11 vg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV2.5-CMV-minidystrophin (d3990)</intervention_name>
    <description>Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known null mutation of the Dystrophin gene

          -  Male age of 5 years or older

          -  If taking corticosteroids, must have dose unchanged for the past 3 months

          -  Serum creatine kinase elevation greater than 10x normal value (established by
             Children's Hospital)

          -  Progressive, symmetrical proximal muscle weakness of arms and legs

        Exclusion Criteria:

          -  Unable to cooperate for muscle strength testing

          -  Joint contractures that prohibit muscle strength testing

          -  Concomitant illness

          -  Individuals predisposed to excessive vagal responses (bradyarrhythmia or hypotension)

          -  Controlled substance abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R. Mendell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ccri.net</url>
    <description>Columbus Children's Research Institute</description>
  </link>
  <link>
    <url>http://www.askbio.com</url>
    <description>Asklepios BioPharmaceutical Inc.</description>
  </link>
  <link>
    <url>http://www.mdausa.org</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <reference>
    <citation>Watchko J, O'Day T, Wang B, Zhou L, Tang Y, Li J, Xiao X. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002 Aug 10;13(12):1451-60.</citation>
    <PMID>12215266</PMID>
  </reference>
  <reference>
    <citation>Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13714-9.</citation>
    <PMID>11095710</PMID>
  </reference>
  <results_reference>
    <citation>Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010 Oct 7;363(15):1429-37. doi: 10.1056/NEJMoa1000228.</citation>
    <PMID>20925545</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012 Feb;20(2):443-55. doi: 10.1038/mt.2011.237. Epub 2011 Nov 8.</citation>
    <PMID>22068425</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Jerry R. Mendell</investigator_full_name>
    <investigator_title>Director Center for Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Duchenne</keyword>
  <keyword>Muscle</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Dystrophin</keyword>
  <keyword>Adeno-Associated Virus</keyword>
  <keyword>AAV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

